Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease

Drug Metabolism and Disposition

Volumn 35, Issue 10, 2007, Pages 1970-1978

  Lickteig, Andrew J ^a   Fisher, Craig D ^a   Augustine, Lisa M ^a   Aleksunes, Lauren M ^b   Besselsen, David G ^a   Slitt, Angela L ^c   Manautou, Jose E ^b   Cherrington, Nathan J ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; CHOLINE; DRUG METABOLITE; EFFLUX TRANSPORTER; MESSENGER RNA; METHIONINE; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; PARACETAMOL; PARACETAMOL GLUCURONIDE; PARACETAMOL GLUTATHIONE; PARACETAMOL SULFATE; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIETARY INTAKE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EXCRETION; FATTY LIVER; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; URINARY EXCRETION;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BILE; DIET; DISEASE MODELS, ANIMAL; FATTY LIVER; MALE; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER;

RATTUS; RODENTIA;

EID: 34748909682     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.015107     Document Type: Article

References (71)

1. Abdelmalek M, Ludwig J, and Lindor KD (1995) Two cases from the spectrum of nonalcoholic steatohepatitis. J Clin Gastroenterol 20:127-130.
2. Abiru S, Migita K, Maeda Y, Daikoku M, Ito M, Ohata K, Nagaoka S, Matsumoto T, Takii Y, Kusumoto K, et al. (2006) Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int 26:39-45.
3. Bahcecioglu IH, Yalniz M, Ataseven H, Ilhan N, Ozercan IH, Seckin D, and Sahin K (2005) Levels of serum hyaluronic acid, TNF-α and IL-8 in patients with nonalcoholic steatohepatitis. Hepatogastroenterology 52:1549-1553.
4. Borst P, Evers R, Kool M, and Wijnholds J (2000) A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295-1302.
5. Brouwer KL and Jones JA (1990) Altered hepatobiliary disposition of acetaminophen metabolites after phenobarbital pretreatment and renal ligation: evidence for impaired biliary excretion and a diffusional barrier. J Pharmacol Exp Ther 252:657-664.
6. Brunt EM and Tiniakos DG (2005) Pathological features of NASH. Front Biosci 10:1475-1484.
7. Büchler M, König J, Brom M, Kartenbeck J, Spring H, Horie T, and Keppler D (1996) cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J Biol Chem 271:15091-15098.
8. Caldwell SH and Hespenheide EE (2002) Subacute liver failure in obese women. Am J Gastroenterol 97:2058-2062.
9. Charlton M, Kasparova P, Weston S, Lindor K, Maor-Kendler Y, Wiesner RH, Rosen CB, and Batts KP (2001) Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 7:608-614.
10. Chawla RK, Watson WH, Eastin CE, Lee EY, Schmidt J, and McClain CJ (1998) S-Adenosylmethionine deficiency and TNF-α in lipopolysaccharide- induced hepatic injury. Am J Physiol 275:G125-G129.
11. Chen C, Hennig GE, and Manautou JE (2003) Hepatobiliary excretion of acetaminophen glutathione conjugate and its derivatives in transport-deficient (TR-) hyperbilirubinemic rats. Drug Metab Dispos 31:798-804.
12. Chen C, Hennig GE, Whiteley HE, Corton JC, and Manautou JE (2000) Peroxisome proliferator-activated receptor α-null mice lack resistance to acetaminophen hepatotoxicity following clofibrate exposure. Toxicol Sci 57:338-344.
13. Chen ZS, Lee K, and Kruh GD (2001) Transport of cyclic nucleotides and estradiol 17-β-D-glucuronide by multidrug resistance protein 4: resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem 276:33747-33754.
14. Cherrington NJ, Hartley DP, Li N, Johnson DR, and Klaassen CD (2002) Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats. J Pharmacol Exp Ther 300:97-104.
15. Cherrington NJ, Slitt AL, Li N, and Klaassen CD (2004) Lipopolysaccharide-mediated regulation of hepatic transporter mRNA levels in rats. Drug Metab Dispos 32:734-741.
16. Congiu M, Mashford ML, Slavin JL, and Desmond PV (2002) UDP glucuronosyltransferase mRNA levels in human liver disease. Drug Metab Dispos 30:129-134.
17. Donner MG and Keppler D (2001) Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver. Hepatology 34:351-359.
18. Farrell GC, Cooksley WG, Hart P, and Powell LW (1978) Drug metabolism in liver disease. Identification of patients with impaired hepatic drug metabolism. Gastroenterology 75:580-588.
19. Farrell GC, Cooksley WG, and Powell LW (1979) Drug metabolism in liver disease: activity of hepatic microsomal metabolizing enzymes. Clin Pharmacol Ther 26:483-492.
20. Figg WD, Dukes GE, Lesesne HR, Carson SW, Songer SS, Pritchard JF, Hermann DJ, Powell JR, and Hak LJ (1995) Comparison of quantitative methods to assess hepatic function: Pugh's classification, indocyanine green, antipyrine, and dextromethorphan. Pharmacotherapy 15:693-700.
21. Forrest JA, Finlayson ND, Adjepon-Yamoah KK, and Prescott LF (1977) Antipyrine, paracetamol, and lignocaine elimination in chronic liver disease. Br Med J 1:1384-1387.
22. Galinsky RE and Levy G (1981) Dose- and time-dependent elimination of acetaminophen in rats: pharmacokinetic implications of cosubstrate depletion. J Pharmacol Exp Ther 219:14-20.
23. Geier A, Dietrich CG, Grote T, Beuers U, Prufer T, Fraunberger P, Matern S, Gartung C, Gerbes AL, and Bilzer M (2005) Characterization of organic anion transporter regulation, glutathione metabolism and bile formation in the obese Zucker rat. J Hepatol 43:1021-1030.
24. Geier A, Dietrich CG, Voigt S, Kim SK, Gerloff T, Kullak-Ublick GA, Lorenzen J, Matern S, and Gartung C (2003) Effects of proinflammatory cytokines on rat organic anion transporters during toxic liver injury and cholestasis. Hepatology 38:345-354.
25. George J, Pera N, Phung N, Leclercq I, Yun HJ, and Farrell G (2003) Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J Hepatol 39:756-764.
26. Grafström R, Ormstad K, Moldéus P, and Orrenius S (1979) Paracetamol metabolism in the isolated perfused rat liver with further metabolism of a biliary paracetamol conjugate by the small intestine. Biochem Pharmacol 28:3573-3579.
27. Green RM, Beier D, and Gollan JL (1996) Regulation of hepatocyte bile salt transporters by endotoxin and inflammatory cytokines in rodents. Gastroenterology 111:193-198.
28. Gregus Z, Madhu C, and Klaassen CD (1988) Species variation in toxication and detoxication of acetaminophen in vivo: a comparative study of biliary and urinary excretion of acetaminophen metabolites. J Pharmacol Exp Ther 244:91-99.
29. Gregus Z, Madhu C, and Klaassen CD (1990) Effect of microsomal enzyme inducers on biliary and urinary excretion of acetaminophen metabolites in rats: decreased hepatobiliary and increased hepatovascular transport of acetaminophen-glucuronide after microsomal enzyme induction. Drug Metab Dispos 18:10-19.
30. Howie D, Adriaenssens PI, and Prescott LF (1977) Paracetamol metabolism following overdosage: application of high performance liquid chromatography. J Pharm Pharmacol 29:235-237.
31. Jonker JW, Buitelaar M, Wagenaar E, van der Valk MA, Scheffer GL, Scheper RJ, Plosch T, Kuipers F, Elferink RP, Rosing H, et al. (2002) The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A 99:15649-15654.
32. Keppler D, Kamisako T, Leier I, Cui Y, Nies AT, Tsujii H, and König J (2000) Localization, substrate specificity, and drug resistance conferred by conjugate export pumps of the MRP family. Adv Enzyme Regul 40:339-349.
33. Keppler D and König J (1997) Expression and localization of the conjugate export pump encoded by the MRP2 (cMRP/cMOAT) gene in liver. FASEB J 11:509-516.
34. Keppler D and König J (2000) Hepatic secretion of conjugated drugs and endogenous substances. Semin Liver Dis 20:265-272.
35. Keppler D, Leier I, and Jedlitschky G (1997) Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2. J Biol Chem 378:787-791.
36. König J, Rost D, Cui Y, and Keppler D (1999) Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology 29:1156-1163.
37. Kopelman PG (2000) Obesity as a medical problem. Nature 404:635-643.
38. Kubitz R, Wettstein M, Warskulat U, and Haussinger D (1999) Regulation of the multidrug resistance protein 2 in the rat liver by lipopolysaccharide and dexamethasone [see comments]. Gastroenterology 116:401-410.
39. Kugelmas M, Hill DB, Vivian B, Marsano L, and McClain CJ (2003) Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 38:413-419.
40. Kuroda M, Kobayashi Y, Tanaka Y, Itani T, Mifuji R, Araki J, Kaito M, and Adachi Y (2004) Increased hepatic and renal expressions of multidrug resistance-associated protein 3 in Eisai hyperbilirubinuria rats. J Gastroenterol Hepatol 19:146-153.
41. Levy G and Yamada H (1971) Drug biotransformation interactions in man. 3. Acetaminophen and salicylamide. J Pharm Sci 60:215-221.
42. Liu RH, Mizuta M, Kurose T, and Matsukura S (2002) Early events involved in the development of insulin resistance in Zucker fatty rat. Int J Obes Relat Metab Disord 26:318-326.
43. Lohr JW, Willsky GR, and Acara MA (1998) Renal drug metabolism. Pharmacol Rev 50:107-141.
44. Manautou JE, de Waart DR, Kunne C, Zelcer N, Goedken M, Borst P, and Elferink RO (2005) Altered disposition of acetaminophen in mice with a disruption of the Mrp3 gene. Hepatology 42:1091-1098.
45. McCullough AJ (2006) Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 40:S17-S29.
46. Mizuno N, Suzuki M, Kusuhara H, Suzuki H, Takeuchi K, Niwa T, Jonker JW, and Sugiyama Y (2004) Impaired renal excretion of 6-hydroxy-5,7-dimethyl-2- methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer resistance protein (BCRP1/ABCG2) knockout mice. Drug Metab Dispos 32:898-901.
47. Moldéus P (1978) Paracetamol metabolism and toxicity in isolated hepatocytes from rat and mouse. Biochem Pharmacol 27:2859-2863.
48. Nadai M, Zhao YL, Wang L, Nishio Y, Takagi K, Kitaichi K, Takagi K, Yoshizumi H, and Hasegawa T (2001) Endotoxin impairs biliary transport of sparfloxacin and its glucuronide in rats. Eur J Pharmacol 432:99-105.
49. Nakanishi T, Doyle LA, Hassel B, Wei Y, Bauer KS, Wu S, Pumplin DW, Fang HB, and Ross DD (2003) Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis. Mol Pharmacol 64:1452-1462.
50. Narang AP, Datta DV, and Mathur VS (1985) Impairment of drug elimination in patients with liver disease. Int J Clin Pharmacol Ther Toxicol 23:28-32.
51. Narang AP, Datta DV, Nath N, and Mathur VS (1981) Pharmacokinetic study of chloramphenicol in patients with liver disease. Eur J Clin Pharmacol 20:479-483.
52. Narang AP, Datta DV, Nath N, and Mathur VS (1982) Impairment of hepatic drug metabolism in patients with acute viral hepatitis. Eur J Drug Metab Pharmacokinet 7:255-258.
53. Oswald S, Haenisch S, Fricke C, Sudhop T, Remmler C, Giessmann T, Jedlitschky G, Adam U, Dazert E, Warzok R, et al. (2006a) Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin Pharmacol Ther 79:206-217.
54. Oswald S, Westrup S, Grube M, Kroemer HK, Weitschies W, and Siegmund W (2006b) Disposition and sterol-lowering effect of ezetimibe in multidrug resistance-associated protein 2-deficient rats. J Pharmacol Exp Ther 318:1293-1299.
55. Pizarro M, Balasubramaniyan N, Solis N, Solar A, Duarte I, Miquel JF, Suchy FJ, Trauner M, Accatino L, Ananthanarayanan M, et al. (2004) Bile secretory function in the obese Zucker rat: evidence of cholestasis and altered canalicular transport function. Gut 53:1837-1843.
56. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, and Powell LW (1990) The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 11:74-80.
57. Schaub TP, Kartenbeck J, Konig J, Vogel O, Witzgall R, Kriz W, and Keppler D (1997) Expression of the conjugate export pump encoded by the mrp2 gene in the apical membrane of kidney proximal tubules. J Am Soc Nephrol 8:1213-1221.
58. Slattery JT and Levy G (1979) Pharmacokinetic model of acetaminophen elimination. Am J Hosp Pharm 36:440.
59. Slitt AL, Cherrington NJ, Maher JM, and Klaassen CD (2003) Induction of multidrug resistance protein 3 in rat liver is associated with altered vectorial excretion of acetaminophen metabolites. Drug Metab Dispos 31:1176-1186.
60. Soroka CJ, Lee J, Azzaroli F, and Boyer JL (2001) Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver. Hepatology 33:783-791.
61. Stärkel P, Sempoux C, Leclercq I, Herin M, Deby C, Desager JP, and Horsmans Y (2003) Oxidative stress, KLF6 and transforming growth factor-β up-regulation differentiate nonalcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats. J Hepatol 39:538-546.
62. Tanaka Y, Slitt AL, Leazer TM, Maher JM, and Klaassen CD (2005) Tissue distribution and hormonal regulation of the breast cancer resistance protein (Bcrp/Abcg2) in rats and mice. Biochem Biophys Res Commun 326:181-187.
63. Vendemiale G, Grattagliano I, Altomare E, Turturro N, and Guerrieri F (1996) Effect of acetaminophen administration on hepatic glutathione compartmentation and mitochondrial energy metabolism in the rat. Biochem Pharmacol 52:1147-1154.
64. Westphal JF and Brogard JM (1997) Drug administration in chronic liver disease. Drug Saf 17:47-73.
65. Whiting JF, Green RM, Rosenbluth AB, and Gollan JL (1995) Tumor necrosis factor-alpha decreases hepatocyte bile salt uptake and mediates endotoxin-induced cholestasis. Hepatology 22:1273-1278.
66. Xiong H, Suzuki H, Sugiyama Y, Meier PJ, Pollack GM, and Brouwer KL (2002) Mechanisms of impaired biliary excretion of acetaminophen glucuronide after acute phenobarbital treatment or phenobarbital pretreatment. Drug Metab Dispos 30:962-969.
67. Xiong H, Turner KC, Ward ES, Jansen PL, and Brouwer KL (2000) Altered hepatobiliary disposition of acetaminophen glucuronide in isolated perfused livers from multidrug resistance-associated protein 2-deficient TR(-) rats. J Pharmacol Exp Ther 295:512-518.
68. Zamek-Gliszczynski MJ, Hoffmaster KA, Humphreys JE, Tian X, Nezasa K, and Brouwer KL (2006a) Differential involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in biliary excretion of 4-methylumbelliferyl glucuronide and sulfate in the rat. J Pharmacol Exp Ther 319:459-467.
69. Zamek-Gliszczynski MJ, Hoffmaster KA, Tian X, Zhao R, Polli JW, Humphreys JE, Webster LO, Bridges AS, Kalvass JC, and Brouwer KL (2005) Multiple mechanisms are involved in the biliary excretion of acetaminophen sulfate in the rat: role of Mrp2 and Bcrp1. Drug Metab Dispos 33:1158-1165.
70. Zamek-Gliszczynski MJ, Nezasa K, Tian X, Bridges AS, Lee K, Belinsky MG, Kruh GD, and Brouwer KL (2006b) Evaluation of the role of multidrug resistance-associated protein (mrp) 3 and mrp4 in hepatic basolateral excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in abcc3-/- and abcc4-/- mice. J Pharmacol Exp Ther 319:1485-1491.
71. Zelcer N, van de Wetering K, Hillebrand M, Sarton E, Kuil A, Wielinga PR, Tephly T, Dahan A, Beijnen JH, and Borst P (2005) Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. Proc Natl Acad Sci U S A 102:7274-7279.